European Journal of Internal Medicine
Volume 21, Issue 4 , Pages 260-267 , August 2010

A closer look at paroxysmal nocturnal hemoglobinuria

  • Saleh Rachidi
    • ,
  • Khaled M. Musallam
    • ,
  • Ali T. Taher

      Affiliations

    • Corresponding Author InformationCorresponding author. Hematology & Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut — Lebanon. Tel.: +961 1 350000; fax: +961 1 370814.

Received 1 February 2010 ,Accepted 5 April 2010.

References 

  1. Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore). 1997;76:63–93
  2. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099–3106
  3. Hill A, Platts PJ, Smith A, Richards SJ, Cullen MJ, Hill QA, et al. The incidence and prevalence of paroxysmal nocturnal haemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Haematologica. 2007;92:25
  4. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–3709
  5. Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318–1320
  6. Kinoshita T, Ohishi K, Takeda J. GPI-anchor synthesis in mammalian cells: genes, their products, and a deficiency. J Biochem. 1997;122:251–257
  7. Tomita M. Biochemical background of paroxysmal nocturnal hemoglobinuria. Biochim Biophys Acta. 1999;1455:269–286
  8. Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria. Haematologica. 2000;85:82–87
  9. Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911–921
  10. Maciejewski JP, Sloand EM, Sato T, Anderson S, Young NS. Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood. 1997;89:1173–1181
  11. Rotoli B, Robledo R, Luzzatto L. Decreased number of circulating BFU-Es in paroxysmal nocturnal hemoglobinuria. Blood. 1982;60:157–159
  12. Young NS. The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood. 1992;79:1385–1392
  13. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol. 1996;3:101–110
  14. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A. 1999;96:5209–5214
  15. Murakami Y, Kinoshita T, Maeda Y, Nakano T, Kosaka H, Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. Blood. 1999;94:2963–2970
  16. Tremml G, Dominguez C, Rosti V, Zhang Z, Pandolfi PP, Keller P, et al. Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood. 1999;94:2945–2954
  17. Kawaguchi T, Nakakuma H. New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2007;86:27–32
  18. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55–CD59− blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–1314
  19. Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R, et al. Emergence of CD52−, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86:1487–1492
  20. Hanaoka N, Kawaguchi T, Horikawa K, Nagakura S, Mitsuya H, Nakakuma H. Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. Blood. 2006;107:1184–1191
  21. Murakami Y, Kosaka H, Maeda Y, Nishimura J, Inoue N, Ohishi K, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–4122
  22. Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1997;94:8756–8760
  23. Savage WJ, Barber JP, Mukhina GL, Hu R, Chen G, Matsui W, et al. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol. 2009;37:42–51
  24. Szpurka H, Schade AE, Jankowska AM, Maciejewski JP. Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells. Br J Haematol. 2008;142:413–422
  25. Lewis SM, Dacie JV. Neutrophil (leucocyte) alkaline phosphatase in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1965;11:549–556
  26. Auditore JV, Hartmann RC, Flexner JM, Balchum OJ. The erythrocyte acetylcholinesterase enzyme in paroxysmal nocturnal hemoglobinuria. Arch Pathol. 1960;69:534–543
  27. Rosse WF, Gutterman LA. The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood. 1970;36:559–565
  28. Hanaoka N, Nakakuma H, Horikawa K, Nagakura S, Tsuzuki Y, Shimanuki M, et al. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. Br J Haematol. 2009;146:538–545
  29. Rosse WF. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1973;24:327–342
  30. Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest. 1966;45:736–748
  31. Rosse WF, Nishimura J. Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems. Int J Hematol. 2003;77:113–120
  32. Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood. 1989;74:437–441
  33. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184–1189
  34. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809–3814
  35. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988;263:18205–18212
  36. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 1989;264:17049–17057
  37. Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991;266:17261–17268
  38. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192–1196
  39. Harmon JT, Jamieson GA. Activation of platelets by alpha-thrombin is a receptor-mediated event. d-Phenylalanyl-l-prolyl-l-arginine chloromethyl ketone-thrombin, but not N alpha-tosyl-l-lysine chloromethyl ketone-thrombin, binds to the high affinity thrombin receptor. J Biol Chem. 1986;261:15928–15933
  40. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995;182:1807–1814
  41. Ploug M, Plesner T, Ronne E, Ellis V, Hoyer-Hansen G, Hansen NE, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 1992;79:1447–1455
  42. Sloand EM, Pfannes L, Scheinberg P, More K, Wu CO, Horne M, et al. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol. 2008;36:1616–1624
  43. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009;113:6522–6527
  44. Ham T. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: a study of the mechanism of hemolysisin relation to acid-base equilibrium. N Engl J Med. 1937;217:915–917
  45. Hartmann RC, Jenkins DE. The “sugar-water” test for paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1966;275:155–157
  46. Bessler M, Fehr J. Fc III receptors (FcRIII) on granulocytes: a specific and sensitive diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH). Eur J Haematol. 1991;47:179–184
  47. Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:5332–5340
  48. Hernandez-Campo PM, Almeida J, Acevedo MJ, Sanchez ML, Alberca I, Vidriales B, et al. Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. Transfusion. 2008;48:1403–1414
  49. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 2000;114:459–466
  50. Ware RE, Pickens CV, DeCastro CM, Howard TA. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp Hematol. 2001;29:1403–1409
  51. Traulsen A, Pacheco JM, Dingli D. On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells. 2007;25:3081–3084
  52. Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopoiesis. Blood. 2005;105:3848–3854
  53. Couturier C, Haeffner-Cavaillon N, Caroff M, Kazatchkine MD. Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J Immunol. 1991;147:1899–1904
  54. Simmons DL, Tan S, Tenen DG, Nicholson-Weller A, Seed B. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood. 1989;73:284–289
  55. Rosse WF. The life-span of complement-sensitive and -insensitive red cells in paroxysmal nocturnal hemoglobinuria. Blood. 1971;37:556–562
  56. Navenot JM, Muller JY, Blanchard D. Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion. 1998;38:337–342
  57. Ninomiya H, Abe T, Fujita T. Prolongation of red-cell life-span by incorporation of decay-accelerating factor (DAF) into red cells of paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol. 1989;73:132–133
  58. Nair RK, Khaira A, Sharma A, Mahajan S, Dinda AK. Spectrum of renal involvement in paroxysmal nocturnal hemoglobinuria: report of three cases and a brief review of the literature. Int Urol Nephrol. 2008;40:471–475
  59. Roubidoux MA. MR of the kidneys, liver, and spleen in paroxysmal nocturnal hemoglobinuria. Abdom Imaging. 1994;19:168–173
  60. Mathieu D, Rahmouni A, Villeneuve P, Anglade MC, Rochant H, Vasile N. Impact of magnetic resonance imaging on the diagnosis of abdominal complications of paroxysmal nocturnal hemoglobinuria. Blood. 1995;85:3283–3288
  61. Jose MD, Lynn KL. Acute renal failure in a patient with paroxysmal nocturnal hemoglobinuria. Clin Nephrol. 2001;56:172–174
  62. Mooraki A, Boroumand B, Mohammad Zadeh F, Ahmed SH Bastani B. Acute reversible renal failure in a patient with paroxysmal nocturnal hemoglobinuria. Clin Nephrol. 1998;50:255–257
  63. Sechi LA, Marigliano A, Pala A, Tedde R. Acute renal failure in paroxysmal nocturnal haemoglobinuria with splanchnic venous thromboses. Clin Lab Haematol. 1989;11:273–275
  64. Rubin H. Paroxysmal nocturnal hemoglobinuria with renal failure. JAMA. 1971;215:433–436
  65. Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood. 1981;57:83–89
  66. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–577
  67. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258
  68. Crosby WH. Paroxysmal nocturnal hemoglobinuria: relation of the clinical manifestations to underlying pathogenic mechanisms. Blood. 1953;8:769–812
  69. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126:133–138
  70. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207
  71. Hartmann RC, Luther AB, Jenkins DE, Tenorio LE, Saba HI. Fulminant hepatic venous thrombosis (Budd-Chiari syndrome) in paroxysmal nocturnal hemoglobinuria: definition of a medical emergency. Johns Hopkins Med J. 1980;146:247–254
  72. Peytremann R, Rhodes RS, Hartmann RC. Thrombosis in paroxysmal nocturnal hemoglobinuria (PNH) with particular reference to progressive, diffuse hepatic venous thrombosis. Ser Haematol. 1972;5:115–136
  73. Hoekstra J, Leebeek FW, Plessier A, Raffa S, Darwish Murad S, Heller J, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol. 2009;51:696–706
  74. Doukas MA, DiLorenzo PE, Mohler DN. Intestinal infarction caused by paroxysmal nocturnal hemoglobinuria. Am J Hematol. 1984;16:75–81
  75. Zimmerman D, Bell WR. Venous thrombosis and splenic rupture in paroxysmal nocturnal hemoglobinuria. Am J Med. 1980;68:275–279
  76. Donhowe SP, Lazaro RP. Dural sinus thrombosis in paroxysmal nocturnal hemoglobinuria. Clin Neurol Neurosurg. 1984;86:149–152
  77. Omardeen F, Wharfe G, St Omer L, Richards JS, Morgan OS. Cerebral sinovenous thrombosis in a patient with paroxysmal nocturnal haemoglobinuria. West Indian Med J. 1992;41:31–33
  78. Hauser D, Barzilai N, Zalish M, Oliver M, Pollack A. Bilateral papilledema with retinal hemorrhages in association with cerebral venous sinus thrombosis and paroxysmal nocturnal hemoglobinuria. Am J Ophthalmol. 1996;122:592–593
  79. Rietschel RL, Lewis CW, Simmons RA, Phyliky RL. Skin lesions in paroxysmal nocturnal hemoglobinuria. Arch Dermatol. 1978;114:560–563
  80. Draelos ZK, Hansen RC. Hemorrhagic bullae in an anemic women. Paroxysmal nocturnal hemoglobinuria (PNH). Arch Dermatol. 1986;122(1326–7):9–30
  81. Hansen NE, Killmann SA. Paroxysmal nocturnal haemoglobinuria. A clinical study. Acta Med Scand. 1968;184:525–541
  82. Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl RL. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol. 2005;252:1379–1386
  83. Tejada J, Hernandez-Echebarria L, Sandoval V, Mostaza JL. Cerebral ischemia as first manifestation of paroxysmal nocturnal hemoglobinuria. Neurologia. 2007;22:471–474
  84. Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol. 2008;6:347–353
  85. Scheuerle AF, Serbecic N, Beutelspacher SC. Paroxysmal nocturnal hemoglobinuria may cause retinal vascular occlusions. Int Ophthalmol. 2009;29:187–190
  86. Fujioka S, Asai T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Nippon Ketsueki Gakkai Zasshi. 1989;52:1386–1394
  87. Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood. 1977;50:657–662
  88. Devine DV, Siegel RS, Rosse WF. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo. J Clin Invest. 1987;79:131–137
  89. Moore JG, Humphries RK, Frank MM, Young N. Characterization of the hematopoietic defect in paroxysmal nocturnal hemoglobinuria. Exp Hematol. 1986;14:222–229
  90. Iwamoto N, Kawaguchi T, Horikawa K, Nagakura S, Kagimoto T, Suda T, et al. Preferential hematopoiesis by paroxysmal nocturnal hemoglobinuria clone engrafted in SCID mice. Blood. 1996;87:4944–4948
  91. Elebute MO, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC, Gibson FM. Evaluation of the haemopoietic reservoir in de novo haemolytic paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2003;123:552–560
  92. Schubert J, Vogt HG, Zielinska-Skowronek M, Freund M, Kaltwasser JP, Hoelzer D, et al. Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood. 1994;83:2323–2328
  93. Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol. 1995;23:81–87
  94. Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, Jonveaux P, Vu T, Bazarbachi A, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood. 1995;85:1354–1363
  95. De Lord C, Tooze JA, Saso R, Marsh JC, Gordon-Smith EC. Deficiency of glycosylphosphatidyl inositol-anchored proteins in patients with aplastic anaemia does not affect response to immunosuppressive therapy. Br J Haematol. 1998;101:90–93
  96. Azenishi Y, Ueda E, Machii T, Nishimura J, Hirota T, Shibano M, et al. CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia. Br J Haematol. 1999;104:523–529
  97. Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401–408
  98. Wang H, Chuhjo T, Yamazaki H, Shiobara S, Teramura M, Mizoguchi H, et al. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001;66:200–205
  99. Iwanaga M, Furukawa K, Amenomori T, Mori H, Nakamura H, Fuchigami K, et al. Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102:465–474
  100. Sears DA, Anderson PR, Foy AL, Williams HL, Crosby WH. Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases. Blood. 1966;28:708–725
  101. Brecher ME, Taswell HF. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited. Transfusion. 1989;29:681–685
  102. Hirsh J, Ungar B, Robinson JS. Paroxysmal nocturnal haemoglobinuria: an acquired dyshaemopoiesis. Australas Ann Med. 1964;13:24–31
  103. Dacie JV. Transfusion of saline-washed red cells in nocturnal haemoglobinuria (Marchiafava–Micheli disease). Clin Sci (Lond). 1948;7:65–75
  104. Hartmann RC, Jenkins DE, McKee LC, Heyssel RM. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron. Medicine (Baltimore). 1966;45:331–363
  105. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373:759–767
  106. Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus. 2004;13:328–334
  107. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–1264
  108. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–559
  109. Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559–2565
  110. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–1243
  111. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–1847
  112. Schubert J, Hillmen P, Roth A, Young NS, Elebute MO, Szer J, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008;142:263–272
  113. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4049–4100
  114. Balleari E, Gatti AM, Mareni C, Massa G, Marmont AM, Ghio R. Recombinant human erythropoietin for long-term treatment of anemia in paroxysmal nocturnal hemoglobinuria. Haematologica. 1996;81:143–147
  115. Schubert J, Scholz C, Geissler RG, Ganser A, Schmidt RE. G-CSF and cyclosporin induce an increase of normal cells in hypoplastic paroxysmal nocturnal hemoglobinuria. Ann Hematol. 1997;74:225–230
  116. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis. 2000;30:103–117
  117. Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood. 1982;60:20–23
  118. McMullin MF, Hillmen P, Jackson J, Ganly P, Luzzatto L. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med. 1994;235:85–89
  119. Sholar PW, Bell WR. Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Ann Intern Med. 1985;103:539–541
  120. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587–3591
  121. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123–4128
  122. Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2009;84:699–701
  123. Stoppa AM, Vey N, Sainty D, Arnoulet C, Camerlo J, Cappiello MA, et al. Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. Br J Haematol. 1996;93:42–44
  124. Paquette RL, Yoshimura R, Veiseh C, Kunkel L, Gajewski J, Rosen PJ. Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1997;96:92–97
  125. Graham ML, Rosse WF, Halperin EC, Miller CR, Ware RE. Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1996;92:707–710
  126. Antin JH, Ginsburg D, Smith BR, Nathan DG, Orkin SH, Rappeport JM. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985;66:1247–1250
  127. Saso R, Marsh J, Cevreska L, Szer J, Gale RP, Rowlings PA, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999;104:392–396
  128. Kawahara K, Witherspoon RP, Storb R. Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 1992;39:283–288
  129. Endo M, Beatty PG, Vreeke TM, Wittwer CT, Singh SP, Parker CJ. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood. 1996;88:742–750
  130. Buchholz S, Dammann E, Koenecke C, Stadler M, Franzke A, Blasczyk R, et al. Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults—a single-centre experience. Ann Hematol. 2008;87:551–556

PII: S0953-6205(10)00063-4

doi: 10.1016/j.ejim.2010.04.002

European Journal of Internal Medicine
Volume 21, Issue 4 , Pages 260-267 , August 2010

Article Tools

* Image Usage & Resolution